Page 12 - TD-3-4

Tumor Discovery Expert consensus of NUT carcinoma

66 Surgical Science Training Center, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore
67 Department of Pathology, Fujian Cancer Hospital Affiliated to Fujian Medical University, Fuzhou, Fujian, China
68 Blokhin National Medical Research Center of Oncology, Ministry of Health, Moscow, Russia
69 Molecular Cancer Genetics and Translational Research Lab, Section of Genetics, Aligarh Muslim University, Aligarh, Uttar Pradesh, India
70 Department of Oncology, Tangdu Hospital, Air Force Medical University, Xi’an, Shaanxi, China
71 Department of Oncology, Chongqing General Hospital, Chongqing University, Shapingba, Chongqing, China
72 Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, China
73 Department of Medical Oncology, Peking University Shenzhen Hospital, Beijing University, Shenzhen, Guangdong, China
74 Department of Molecular Pathology, Henan Key Laboratory of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University
& Henan Cancer Hospital, Zhengzhou, Henan, China
75 National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking
Union Medical College, Beijing, China
76 Department of Gastrointestinal Surgery, Affiliated Tumor Hospital of Nantong University, Nantong Tumor Hospital, Nantong, Jiangsu, China
77 Endoscopy Center of the Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China
78 Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
79 Department of Pulmonary Gastroenterology, Hunan Cancer Hospital, Changsha, Hunan, China
80 Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, Guangdong Institute of Gastroenterology; Department of
Clinical Laboratory, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
81 Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor Biological
Behaviors Hubei Cancer Clinical Study Center, Wuhan, Hubei, China
82 Department of Oncology, Southwest Hospital, Third Military Medical University (Army Medical University), Shapingba, Chongqing, China
83 Department of General Thoracic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China
84 Department of Oncology, Xijing Hospital, Air Force Medical University, Xincheng, Xi’an, Shaanxi, China
85 Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang,
China
86 Research Center of Cancer Diagnosis and Therapy, Department of Oncology, The First Affiliated Hospital of Jinan University, Guangzhou,
Guangdong, China
87 Department of Oncology, Shaanxi Cancer Hospital, Xi’an, Shaanxi, China
88 Breast Disease Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
89 State Key Laboratory of Respiratory Diseases, National Clinical Research Center for Respiratory Diseases, Guangzhou Institute of
Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
90 Department of Oncology, People’s Hospital of Shapingba, Shapingba, Chongqing, China
91 Department of Oncology, Xiangya Hospital, Central South University, No. 87, Changsha, Hunan, China
92 Guangdong-Hong Kong-Macau Great Bay Area Geroscience Joint Laboratory, School of Medicine, Jinan University, Guangzhou, China
93 Department of Pathology, Yale Center for Immuno-Oncology, Yale Cancer Center, Yale University, New Haven, Connecticut, United States
of America

1. Introduction glands, central nervous system (CNS), and soft tissues.
As a result, the World Health Organization renamed
Nuclear protein of the testis (NUT) carcinoma, also known
as midline carcinoma resulting from the rearrangement of the condition “NUT carcinoma” to better reflect its
5-15
the NUT gene, is a rare and highly aggressive malignant broader clinical presentation. The rearrangement of
tumor. It is associated with rearranging the NUT the NUTM1 gene was initially considered a hallmark
midline carcinoma family member 1 (NUTM1) gene on molecular alteration in NUT carcinoma. In recent years,
chromosome 15q14. First described in 1991, subsequent NUTM1 rearrangements have also been identified in
cases of NUT carcinoma have primarily been reported tumor types, such as round-cell sarcoma, acute leukemia,
in the midline structures of the human body, including hidradenoma, and hidradenocarcinoma, broadening
the head, neck, and thoracic/mediastinal regions, which the spectrum of diseases associated with this genetic
is why it was initially termed “midline carcinoma.” change. Multiple partner genes that can fuse with NUTM1
1-4
However, NUT carcinoma can also occur in various have now been identified, including members of the
organs, including the lungs, bones, nasal cavity, salivary bromodomain protein family, the myelocytomatosis-

Volume 3 Issue 4 (2024) 4 doi: 10.36922/td.4904